BVS Bears Ease Back Ahead of Q3 Print

Bioventus heads into today's Q3 results with short sellers trimming exposure even as the stock pulls back sharply from its 2026 highs.

The clearest signal in the positioning data is the retreat of short sellers. Short interest has fallen roughly 0.7% over the past week to 4.7% of the free float. The month-over-month picture is less clean, short positions have grown about 4.5% from late September, but the directional drift into the print is lower. Borrow conditions provide no particular friction: cost to borrow has ticked up around 20% week-on-week but remains low in absolute terms at 0.63%. Availability is ample at 200%, meaning there are roughly two shares available to borrow for every one already lent out. There is no squeeze pressure here. Options traders are leaning the same way: the put/call ratio of 0.035 is below its 20-day average and near the 52-week low of 0.031, a signal that call demand dominates and downside protection is not a priority for the options market.

The price action complicates that picture. BVS has dropped 10.7% over the past week to $13.15, a notable reversal for a stock that was up well over 70% year-to-date just weeks ago. Correlated peers also weakened: ENOV fell 12.7% on the day alone, MMSI lost 7.7% on the week, and RMD dropped 9.1% over the same period, suggesting sector-level pressure rather than a BVS-specific deterioration. That context matters when reading the options and short positioning as bullish: the broader med-tech group is being sold.

The bull and bear cases are well established among the handful of analysts who cover the name. Bulls point to the Exogen bone stimulation system driving surgical solutions revenue growth above 10%, management's guidance for low-double-digit growth in that segment through 2026, and a trajectory toward significantly wider EBITDA margins by 2030. Bears focus on restorative therapies revenue falling 26%, an international revenue decline of 8.6%, and elevated investment spending that holds margin expansion at bay near-term. The analyst consensus as of mid-August remained constructive, with Canaccord Genuity raising its target to $19 following last quarter's results and the mean target from available coverage sitting well above the current price. However, given the stock's steep pullback from those levels and the absence of fresh analyst commentary since August, the gap between target and price reflects how much the stock has already moved rather than fresh conviction.

Ownership concentration is worth noting into the print. Essex Woodlands holds 19% of shares, Juniper Investment holds a further 10%, and Smith & Nephew carries 9%. These three top holders alone account for nearly 40% of the company. A meaningful post-earnings move could be amplified by the thinness of the float relative to institutional concentration.

Today's print is ultimately a test of whether Bioventus can show enough progress in surgical solutions and margin trajectory to justify re-engagement after a week of heavy selling, in a sector where patience for investment-phase earnings has been short.